JP2003238383A - Skin care preparation - Google Patents
Skin care preparationInfo
- Publication number
- JP2003238383A JP2003238383A JP2002036377A JP2002036377A JP2003238383A JP 2003238383 A JP2003238383 A JP 2003238383A JP 2002036377 A JP2002036377 A JP 2002036377A JP 2002036377 A JP2002036377 A JP 2002036377A JP 2003238383 A JP2003238383 A JP 2003238383A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- external preparation
- acid
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 38
- 241000196324 Embryophyta Species 0.000 claims abstract description 31
- 230000017531 blood circulation Effects 0.000 claims abstract description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 9
- 235000020224 almond Nutrition 0.000 claims abstract description 9
- 241001116389 Aloe Species 0.000 claims abstract description 8
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 8
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 244000105624 Arachis hypogaea Species 0.000 claims abstract description 4
- 235000000832 Ayote Nutrition 0.000 claims abstract description 4
- 240000004244 Cucurbita moschata Species 0.000 claims abstract description 4
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 4
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 4
- 244000000626 Daucus carota Species 0.000 claims abstract description 4
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 4
- 235000004347 Perilla Nutrition 0.000 claims abstract description 4
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 4
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 4
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 4
- 235000020232 peanut Nutrition 0.000 claims abstract description 4
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 4
- 235000017060 Arachis glabrata Nutrition 0.000 claims abstract description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 claims abstract description 3
- 235000018262 Arachis monticola Nutrition 0.000 claims abstract description 3
- 230000010261 cell growth Effects 0.000 claims description 11
- 239000007952 growth promoter Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 3
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 230000008961 swelling Effects 0.000 abstract description 10
- 230000037303 wrinkles Effects 0.000 abstract description 10
- 244000077995 Coix lacryma jobi Species 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 241000533367 Cnidium officinale Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 235000006754 Taraxacum officinale Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 28
- 239000009538 yokuinin Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- -1 2-phenoxyethanol Chemical class 0.000 description 19
- 230000006872 improvement Effects 0.000 description 13
- 239000006071 cream Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 239000004359 castor oil Substances 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 235000019438 castor oil Nutrition 0.000 description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002280 amphoteric surfactant Substances 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- RKJGFHYCZPZJPE-UHFFFAOYSA-N 2,2-bis(16-methylheptadecanoyloxymethyl)butyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C RKJGFHYCZPZJPE-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- MXVBVDSNBADJOC-UHFFFAOYSA-N 2-(4,5-dihydroimidazol-1-yl)-4-hydroxybutanoic acid;sodium Chemical compound [Na].OCCC(C(O)=O)N1CCN=C1 MXVBVDSNBADJOC-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LNCJHVLXANMHHD-UHFFFAOYSA-N 2-[2-heptadecyl-1-(2-hydroxyethyl)-4,5-dihydroimidazol-1-ium-1-yl]acetate Chemical compound CCCCCCCCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O LNCJHVLXANMHHD-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- JVXJFNLEXLGQIO-UHFFFAOYSA-N 2-hexyldecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC JVXJFNLEXLGQIO-UHFFFAOYSA-N 0.000 description 1
- OGJDIJKJFYOENF-UHFFFAOYSA-N 2-hexyldecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC OGJDIJKJFYOENF-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LCPHRNNQHHQGLY-UHFFFAOYSA-N 3,3-dimethyl-3-azoniabicyclo[3.1.1]heptane Chemical compound C1[N+](C)(C)CC2CC1C2 LCPHRNNQHHQGLY-UHFFFAOYSA-N 0.000 description 1
- ZQXRINMCMHCYBD-UHFFFAOYSA-N 4-(2-ethylhexoxy)-4-oxobutanoic acid Chemical compound CCCCC(CC)COC(=O)CCC(O)=O ZQXRINMCMHCYBD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- GQXQIRNPJBUEGY-UHFFFAOYSA-N hexadecan-7-yl 2,2-dimethyloctanoate Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)C(C)(C)CCCCCC GQXQIRNPJBUEGY-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 1
- DFIWJEVKLWMZBI-UHFFFAOYSA-M sodium;dihydrogen phosphate;phosphoric acid Chemical compound [Na+].OP(O)(O)=O.OP(O)([O-])=O DFIWJEVKLWMZBI-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229940118594 trimethylolpropane triisostearate Drugs 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、皮膚外用剤に係
り、更に詳細には、クマ、小じわ及びむくみを改善し得
る目元向き又は目元用の皮膚外用剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin, and more particularly to an external preparation for or around the eyes which can improve bears, fine lines and swelling.
【0002】[0002]
【従来の技術】従来より、ヨクイニンは保湿効果や消炎
効果などを有する生薬として知られており、その応用例
としては、ヨクイニンを加水分解して得られた糖類及び
アミノ酸を主成分とする特殊なエキスを含有し、保湿作
用、乳化安定性及び抗酸化作用などを有する皮膚化粧料
が開示されている(特公平3−33684号公報)。ま
た、特開平11−228436号公報には、津液改善作
用を有する生薬のエッセンスとしてヨクイニンやヨクイ
ニンエキスが記載されている。2. Description of the Prior Art Yokuinin has been known as a herbal medicine having a moisturizing effect and an anti-inflammatory effect, and its application example is a special drug containing saccharides and amino acids obtained by hydrolyzing Yokuinin as a main component. A skin cosmetic containing an extract and having a moisturizing action, an emulsion stability, an antioxidant action and the like has been disclosed (Japanese Patent Publication No. 3-36884). Further, Japanese Patent Application Laid-Open No. 11-228436 describes Yokuinin and Yokuinin extract as the essence of a crude drug having a tsu liquid improving effect.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、これら
従来技術においては、ヨクイニンやヨクイニンエキスが
単独で用いられており、他成分との配合組成物について
の所見は開示されておらず、特開平11−228436
号公報においても、実際にはヨクイニンエキス単独の効
能が検討されているに過ぎない(特に同公報の「実施
例」参照)。また、これら従来技術において検討されて
いるのは、一般的な化粧料や食品としての有用性であ
り、目元向きないしは目元専用の外用剤としての検討は
全くされていない。However, in these prior arts, Yokuinin and Yokuinin extract are used alone, and there is no disclosure of a finding of a compounded composition with other components. 228436
In the gazette, actually, the efficacy of Yokuinin extract alone is only examined (see especially "Example" of the gazette). Further, what has been studied in these conventional techniques is usefulness as general cosmetics and foods, and no study as an external preparation suitable for the eyes or exclusively for the eyes has been made.
【0004】本発明は、このような従来技術の有する課
題に鑑みてなされたものであり、その目的とするところ
は、ヨクイニンを含有する新規用途に係る組成物であっ
て、クマ、小じわ及びむくみを改善し得る目元向き又は
目元用の皮膚外用剤を提供することにある。The present invention has been made in view of the above problems of the prior art, and an object of the present invention is to provide a new use composition containing yochinin, which includes bear, fine wrinkles and swelling. An object is to provide a skin external preparation for or around the eyes that can improve the above.
【0005】[0005]
【課題を解決するための手段】本発明者らは、上記課題
を解決すべく鋭意検討を重ねた結果、ヨクイニンに所定
成分を配合したところ、特に目元に生ずるクマや小じわ
などが改善されることを見出し、本発明を完成するに至
った。Means for Solving the Problems As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that when Yokuinin is blended with predetermined components, bears, fine wrinkles, etc., which occur especially around the eyes, are improved. The present invention has been completed and the present invention has been completed.
【0006】即ち、本発明の目元向き皮膚外用剤は、ヨ
クイニン及び/又はその抽出物と、細胞増殖促進剤と、
血行促進剤とを配合して成ることを特徴とする。[0006] That is, the external preparation for skin for the eyes of the present invention comprises Yokuinin and / or its extract, a cell growth promoter, and
It is characterized by being mixed with a blood circulation promoter.
【0007】また、本発明の皮膚外用剤の好適形態は、
上記細胞増殖促進剤が、アロエ、セイヨウタンポポ、セ
ンキュウ、ソウハクヒ、ニンジン及びホップから成る群
より選ばれた少なくとも1種の植物、及び/又はこれら
の植物若しくは植物の組合せからの抽出物であり、上記
血行促進剤が、ビタミンE及び/又はその誘導体である
ことを特徴とする。この場合、上記血行促進剤として
は、アーモンド、落花生、シソ及びカボチャから成る群
より選ばれた少なくとも1種の植物、及び/又はこれら
の植物若しくは植物の組合せからの抽出物も適用可能で
ある。The preferred form of the external preparation for skin of the present invention is
The cell growth promoter is at least one plant selected from the group consisting of aloe, dandelion, senkyu, sokuhaku, carrot and hop, and / or an extract from these plants or a combination of plants, It is characterized in that the accelerator is vitamin E and / or a derivative thereof. In this case, as the blood circulation promoter, at least one plant selected from the group consisting of almond, peanut, perilla and pumpkin, and / or an extract from these plants or a combination of plants is also applicable.
【0008】更に、本発明の皮膚外用剤の他の好適形態
は、ペンタンジオールを更に配合して成ることを特徴と
し、防腐剤を含有しないことが望ましい。更にまた、本
発明の皮膚外用剤の更に他の好適形態は、目元に用いる
ことを特徴とする。Further, another preferred form of the external preparation for skin of the present invention is characterized in that it is further blended with pentanediol, and it is desirable not to contain a preservative. Still another preferred embodiment of the external preparation for skin of the present invention is characterized in that it is used for the eyes.
【0009】[0009]
【発明の実施の形態】以下、本発明の目元向き皮膚外用
剤について詳細に説明する。なお、本明細書において、
「%」は特記しない限り、質量百分率を示すものとす
る。上述の如く、本発明の目元向き皮膚外用剤は、ヨク
イニン又はその抽出物及び両者の混合物と、細胞増殖促
進剤と、血行促進剤とを含有する。BEST MODE FOR CARRYING OUT THE INVENTION The external preparation for skin for eyes according to the present invention will be described in detail below. In the present specification,
Unless otherwise specified, "%" means mass percentage. As described above, the eye external preparation for skin of the present invention contains yochinin or an extract thereof and a mixture of both, a cell growth promoter and a blood circulation promoter.
【0010】ここで、ヨクイニン及びその抽出物として
は、従来公知のものを使用でき、市場で入手し得るもの
を使用可能である。この点において、特公平3−336
84号公報に記載されているような特殊なヨクイニンエ
キスを用いる必要はない。ヨクイニンの抽出物として
は、ハトムギの実から抽出されるヨクイニンエキスが有
名であり、市販されているが、これらは保湿効果や消炎
効果を有するとされている。本発明の皮膚外用剤におい
て、ヨクイニン又はヨクイニンエキスは、主として、目
元の水分代謝を促進し、むくみのない状態を実現する機
能を担う。Here, as Yokuinin and its extract, conventionally known ones can be used, and those commercially available can be used. In this regard, Japanese Patent Publication No. 3-336
It is not necessary to use a special Yokuinin extract as described in Japanese Patent No. 84. As an extract of Yokuinin, Yokuinin extract extracted from the seeds of Coix seeds is well known and commercially available, but these are said to have a moisturizing effect and an anti-inflammatory effect. In the external preparation for skin of the present invention, Yokuinin or Yokuinin extract mainly has a function of promoting the water metabolism of the eyes and realizing a non-swelling state.
【0011】次に、細胞増殖促進剤としては、主として
保湿効果やバリア機能を発揮することにより、細胞、特
に目元の皮膚細胞が増殖するのを促進できれば特に限定
されず、アロエ、セイヨウタンポポ、センキュウ、ソウ
ハクヒ、ニンジン又はホップなどの植物、及びこれら植
物の抽出物を例示することができるが、特にアロエ及び
アロエ抽出物を好適に用いることができる。また、本発
明の皮膚外用剤では、かかる植物及びその抽出物を単独
で又は任意に組み合わせて使用することができる。な
お、本発明の皮膚外用剤において、細胞増殖促進剤は、
主として、目元肌の乾燥を防止し、小じわの発生を抑制
するとともに、発生した小じわを改善・除去する機能を
担う。The cell growth promoter is not particularly limited as long as it can promote the growth of cells, especially the skin cells around the eyes, mainly by exerting a moisturizing effect and a barrier function, and includes aloe, dandelion, senkyu, Examples thereof include plants such as souah, carrots and hops, and extracts of these plants, and aloe and aloe extract are particularly preferably used. Further, in the external preparation for skin of the present invention, such plants and extracts thereof can be used alone or in any combination. In the external preparation for skin of the present invention, the cell growth promoter is
It mainly prevents the skin around the eyes from drying and suppresses the generation of fine wrinkles, and also has the function of improving and removing the fine lines that have occurred.
【0012】通常、上述のような植物は、その植物自
体、又はその植物を乾燥、細切及び粉砕などして加工し
た加工物として使用される。一方、このような植物の抽
出物は、その植物又は植物の加工物を溶媒で抽出した抽
出物、圧搾や水蒸気蒸留などを行って得られる液体を捕
集した留分、及びこのような抽出物や留分を液液抽出や
カラムクロマトグラフィーで精製した精製物などとして
使用される。なお、このような植物及びその抽出物につ
いての記載内容は、上述したヨクイニンとヨクイニン抽
出物にも当てはまる。[0012] Usually, the above-mentioned plant is used as the plant itself or a processed product obtained by processing the plant by drying, shredding and crushing. On the other hand, such a plant extract is an extract obtained by extracting the plant or a processed product of the plant with a solvent, a fraction obtained by collecting a liquid obtained by squeezing or steam distillation, and such an extract. It is used as a purified product obtained by liquid-liquid extraction or column chromatography of the fraction or fraction. In addition, the description about such a plant and its extract also applies to the above-mentioned Yokuinin and Yokuinin extract.
【0013】また、上述のような抽出物としては、いわ
ゆるエキスが代表的であり、かかるエキスは、当該植物
を極性溶媒で抽出したり、酸加水分解、酵素分解又は熱
水抽出等により溶解させた後に濾過したり、当該溶液を
乾燥し極性溶媒で抽出したりすることなどによって得ら
れるが、本発明では極性溶媒で抽出する方法が好まし
い。なお、抽出に供する植物は、乾燥及び/又は粉砕す
ることができ、また抽出溶媒中でホモジナイズしたり、
超音波で破砕してもよい。抽出溶媒としては、水や極性
有機溶媒などを使用できる。この極性有機溶媒として
は、代表的には、メタノール、エタノール、プロパノー
ル及びイソプロパノール等の低級アルコール、1,3−
ブチレングリコール、プロピレングリコール、ジプロピ
レングリコール及びグリセリン等の多価アルコール、エ
チルエーテル及びプロピルエーテル等のエーテル類、酢
酸エチル及び酢酸ブチル等のエステル類、並びにアセト
ン及びエチルメチルケトン等のケトン類などを挙げるこ
とができ、これらを任意に組合せた溶媒も使用可能であ
る。A so-called extract is typically used as the extract as described above. Such an extract is obtained by extracting the plant with a polar solvent or dissolving it by acid hydrolysis, enzymatic decomposition or hot water extraction. It can be obtained by, for example, filtering or drying the solution and extracting with a polar solvent, but in the present invention, a method of extracting with a polar solvent is preferable. The plant used for extraction can be dried and / or pulverized, and can be homogenized in an extraction solvent,
It may be crushed by ultrasonic waves. Water or a polar organic solvent can be used as the extraction solvent. Typical examples of the polar organic solvent include lower alcohols such as methanol, ethanol, propanol and isopropanol, and 1,3-
Examples include polyhydric alcohols such as butylene glycol, propylene glycol, dipropylene glycol and glycerin, ethers such as ethyl ether and propyl ether, esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone. It is also possible to use a solvent in which these are arbitrarily combined.
【0014】次に、血行促進剤としては、血行を促進で
きる限り特に限定されるものではないが、代表的には、
ビタミンE又はその誘導体、及び両者の混合物を挙げる
ことができる。また、ビタミンEを多く含有する植物及
びその抽出物も好適であり、具体的には、アーモンド、
落花生、シソ又はカボチャなどの植物、及びこれら植物
の抽出物を例示でき、本発明では、これら植物や植物抽
出物を任意に組み合わせて使用することができる。な
お、これらのうちで最も好ましいのは、アーモンド及び
アーモンド抽出物である。また、植物及び植物の抽出物
についての意味は上述の通りであり、本発明の皮膚外用
剤においては、各種植物のエキスを好適に使用できる。
本発明の皮膚外用剤において、血行促進剤は、主として
目元にクマが発生するのを抑制するとともに、発生した
クマを改善・除去する機能を担う。The blood circulation promoter is not particularly limited as long as it can promote blood circulation, but typically,
Mention may be made of vitamin E or its derivatives, and mixtures of both. Further, a plant containing a large amount of vitamin E and an extract thereof are also suitable, and specifically, almond,
Peanuts, plants such as perilla or pumpkin, and extracts of these plants can be exemplified, and in the present invention, these plants and plant extracts can be used in any combination. The most preferable of these are almonds and almond extracts. The meanings of plants and plant extracts are as described above, and various plant extracts can be preferably used in the skin external preparation of the present invention.
In the external preparation for skin of the present invention, the blood circulation promoter mainly has a function of suppressing the generation of bears around the eyes and of improving and removing the generated bears.
【0015】本発明の皮膚外用剤において、上述した必
須3成分の配合比は、特に限定されるものではなく、意
図する改善効果の発現度合いや使用者の体質、使用する
具体的成分などに応じて適宜変更することができるが、
代表的には、ヨクイニン及び/又はその抽出物を0.0
001〜10%、細胞増殖促進剤を0.0001〜10
%、血行促進剤を0.0001〜10%の割合で配合す
ることが好ましい。ヨクイニン及び/又はその抽出物、
並びに細胞増殖促進剤の配合量が0.0001%未満で
は、意図する効果が発揮されないことがあり、10%を
超えると、配合する植物が日光下や高温環境下で変性し
て効果が低減したり、化粧料としての嗜好上好ましくな
いにおいが発生することがある。また、血行促進剤の配
合量が0.0001%未満では、意図する効果が得られ
ないことがあり、10%を超えると、皮膚の薄い目元に
使用する観点からは皮膚刺激になってしまうことがあ
る。In the external preparation for skin of the present invention, the compounding ratio of the above-mentioned three essential components is not particularly limited, and depends on the degree of intended improvement effect, the physical constitution of the user, the specific components used, and the like. Can be changed as appropriate,
Typically, Yokuinin and / or its extract is added to 0.0
001-10%, cell growth promoter 0.0001-10
%, And the blood circulation promoter is preferably blended at a ratio of 0.0001 to 10%. Yokuinin and / or its extract,
In addition, if the content of the cell growth promoter is less than 0.0001%, the intended effect may not be exhibited. If it exceeds 10%, the plant to be compounded will be denatured in the sunlight or high temperature environment, and the effect will be reduced. Or, an unpleasant odor due to the taste as a cosmetic may occur. Also, if the content of the blood circulation promoter is less than 0.0001%, the intended effect may not be obtained, and if it exceeds 10%, it may cause skin irritation from the viewpoint of use on thin skin areas. There is.
【0016】本発明の皮膚外用剤は、上述の3成分を必
須成分とするが、化粧水、乳液及びクリームなどの製品
形態やその他の必要性に応じて他の任意成分を添加する
ことができる。例えば、本発明の皮膚外用剤には一般的
な防腐剤を適宜添加でき、この場合、防腐剤の具体例と
しては、イソプロピルメチルフェノール、パラオキシ安
息香酸エステル及び2−フェノキシエタノール等のフェ
ノール類、安息香酸、サリチル酸、デヒドロ酢酸及びソ
ルビン酸等の酸類及びそれらの塩、塩化ベンザルコニウ
ム、塩化ベンゼトニウム及び塩化アルキルトリメチルア
ンモニウム等の第4級アンモニウム塩、塩酸アルキルア
ミノエチルグリシン、塩化ステアリルヒドロキシエチル
ベタイン及びナトリウム等の両性界面活性剤、並びに感
光素などを挙げることができる。The external preparation for skin of the present invention contains the above-mentioned three components as essential components, but other optional components can be added depending on the product form such as lotion, emulsion and cream and other needs. . For example, a general preservative can be appropriately added to the skin external preparation of the present invention. In this case, specific examples of the preservative include isopropylmethylphenol, paraoxybenzoic acid ester and phenols such as 2-phenoxyethanol, and benzoic acid. , Acids such as salicylic acid, dehydroacetic acid and sorbic acid and salts thereof, quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride and alkyltrimethylammonium chloride, alkylaminoethylglycine hydrochloride, stearyl hydroxyethyl betaine and sodium, etc. And amphoteric surfactants, as well as photosensitizers.
【0017】なお、本発明の皮膚外用剤においては、炭
素数4〜7のジオール類を添加して皮膚穏和性の更なる
向上や所期効果の低減を抑制しつつ、長期間の保存を可
能にすることができる。このようなジオール類を用いれ
ば各種防腐剤の使用は不要となる。かかるジオール類と
しては、1,2−ペンタンジオールが好適である。1,
2−ペンタンジオールは、皮膚外用剤の総重量に対して
0.5〜20%の割合で含有させることが望ましい。In addition, in the external preparation for skin of the present invention, diols having 4 to 7 carbon atoms are added to enable further long-term storage while suppressing further improvement of skin mildness and reduction of desired effects. Can be If such diols are used, it is not necessary to use various preservatives. As such diols, 1,2-pentanediol is preferable. 1,
2-Pentanediol is preferably contained in a proportion of 0.5 to 20% with respect to the total weight of the external preparation for skin.
【0018】本発明の皮膚外用剤を適用し得る製品形態
としては、洗顔料類、ローション類、乳液類、クリーム
類及びパック類などを挙げることができる。また、これ
ら製品には、必要に応じて、保湿剤、アミノ酸、ビタミ
ン類、炭化水素、高級脂肪酸、エステル類、シリコー
ン、アニオン性界面活性剤、カチオン性界面活性剤、両
性界面活性剤、非イオン性界面活性剤、水溶性高分子、
pH調整剤及び水等を適宜添加することができる。これ
らの成分は単独で添加してもよいし、2種以上を混合し
て添加してもよい。Examples of product forms to which the external preparation for skin of the present invention can be applied include face wash, lotions, emulsions, creams and packs. In addition, these products may contain moisturizers, amino acids, vitamins, hydrocarbons, higher fatty acids, esters, silicones, anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, as necessary. Surfactant, water-soluble polymer,
A pH adjuster, water and the like can be added as appropriate. These components may be added alone, or two or more kinds may be mixed and added.
【0019】上記保湿剤としては、例えば、ポリエチレ
ングリコール、プロピレングリコール、グリセリン、
1,3−ブチレングリコール、ソルビトール、マルチト
ール、コンドロイチン硫酸、ヒアルロン酸、コラーゲ
ン、乳酸ナトリウム、dl−ピロリドンカルボン酸塩、
黒糖抽出物及びキトサン誘導体などが挙げられる。ま
た、上記アミノ酸としては、例えば、グリシン、アラニ
ン、バリン、ロイシン、イソロイシン、セリン、スレオ
ニン、トリプトファン、シスチン、メチオニン、プロリ
ン、ヒドロキシプロリン、グルタミン及びアスパラギン
等の中性アミノ酸や、アスパラギン酸及びグルタミン酸
等の酸性アミノ酸や、アルギニン、ヒスチジン、リジン
及びヒドロキシリジン等の塩基性アミノ酸などが挙げら
れる。更に、上記ビタミン類としては、ビタミンA、B
1、B2、B6、C及びその誘導体、ビタミンE及びそ
の誘導体、パントテン酸及びその誘導体、並びにビオチ
ン等が挙げられる。Examples of the moisturizers include polyethylene glycol, propylene glycol, glycerin,
1,3-butylene glycol, sorbitol, maltitol, chondroitin sulfate, hyaluronic acid, collagen, sodium lactate, dl-pyrrolidone carboxylate,
Examples include brown sugar extract and chitosan derivative. Examples of the amino acid include neutral amino acids such as glycine, alanine, valine, leucine, isoleucine, serine, threonine, tryptophan, cystine, methionine, proline, hydroxyproline, glutamine and asparagine, and aspartic acid and glutamic acid. Examples thereof include acidic amino acids and basic amino acids such as arginine, histidine, lysine and hydroxylysine. Furthermore, as the above-mentioned vitamins, vitamins A and B
1, B2, B6, C and its derivatives, vitamin E and its derivatives, pantothenic acid and its derivatives, and biotin.
【0020】更にまた、上記炭化水素としては、流動パ
ラフィン、パラフィン、スクワラン及びワセリン等が挙
げられる。また、上記高級脂肪酸としては、例えば、ラ
ウリン酸、ミリスチン酸、パルミチン酸、ステアリン
酸、ベヘニン酸、オレイン酸、12−ヒドロキシステア
リン酸、ウンデシレン酸、イソステアリン酸、リノール
酸、リノレイン酸、エイコサペンタエン酸(EPA)及
びドコサヘキサエン酸(DHA)等が挙げられる。Furthermore, examples of the above-mentioned hydrocarbon include liquid paraffin, paraffin, squalane, petrolatum and the like. Examples of the higher fatty acid include lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, 12-hydroxystearic acid, undecylenic acid, isostearic acid, linoleic acid, linoleic acid, eicosapentaenoic acid ( EPA) and docosahexaenoic acid (DHA).
【0021】更に、上記エステル類としては、ミリスチ
ン酸イソプロピル、オクタン酸セチル、ミリスチン酸オ
クチルドデシル、パルミチン酸イソプロピル、ステアリ
ン酸ブチル、ラウリン酸ヘキシル、ミリスチン酸ミリス
チル、オレイン酸デシル、ジメチルオクタン酸ヘキシル
デシル、乳酸セチル、乳酸ミリスチル、酢酸ラノリン、
ステアリン酸イソセチル、イソステアリン酸イソセチ
ル、2−ヒドロキシステアリル酸コレステリル、ジ−2
−エチルヘキシル酸エチレングリコール、ジペンタエリ
スリトール脂肪酸エステル、モノイソステアリン酸N−
アルキルグリコール、ジカプリン酸ネオペンチルグリコ
ール、リンゴ酸ジイソステアリル、ジ−2−ヘプチルウ
ンデカン酸グリセリン、トリ−2−エチルヘキシル酸グ
リセリン、トリイソステアリン酸トリメチロールプロパ
ン、セチル2−エチルヘキサノエート、2−エチルヘキ
シルパルミテート、トリミリスチン酸グリセリン、トリ
−2−ヘプチルウンデカン酸グリセライド、ヒマシ油脂
肪酸メチルエステル、ミリスチン酸2−ヘキシルデシ
ル、パルミチン酸2−ヘキシルデシル、アジピン酸2−
ヘキシルデシル、セバチン酸ジイソプロピル、コハク酸
2−エチルヘキシル及びクエン酸トリエチル等が挙げら
れる。Further, as the above-mentioned esters, isopropyl myristate, cetyl octanoate, octyldodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyldecyl dimethyloctanoate, Cetyl lactate, myristyl lactate, lanolin acetate,
Isocetyl stearate, isocetyl isostearate, cholesteryl 2-hydroxystearate, di-2
-Ethylene glycol ethylhexylate, dipentaerythritol fatty acid ester, monoisostearic acid N-
Alkyl glycol, neopentyl glycol dicaprate, diisostearyl malate, glycerin di-2-heptylundecanoate, glyceryl tri-2-ethylhexylate, trimethylolpropane triisostearate, cetyl 2-ethylhexanoate, 2-ethylhexyl Palmitate, glycerin trimyristate, tri-2-heptylundecanoic acid glyceride, castor oil fatty acid methyl ester, 2-hexyldecyl myristate, 2-hexyldecyl palmitate, adipic acid 2-
Hexyldecyl, diisopropyl sebacate, 2-ethylhexyl succinate, triethyl citrate and the like can be mentioned.
【0022】更にまた、上記シリコーンとしては、例え
ば、ジメチルポリシロキサン及びメチルフェニルポリシ
ロキサン等の鎖状ポリシロキサン、デカメチルシクロペ
ンタシロキサン及びドデカメチルシクロヘキサシロキサ
ン等の環状ポリシロキサン、3次元網目構造を形成して
いるシリコン樹脂等が挙げられる。Furthermore, examples of the silicone include chain polysiloxanes such as dimethylpolysiloxane and methylphenylpolysiloxane, cyclic polysiloxanes such as decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane, and three-dimensional network structures. The silicon resin etc. which are formed are mentioned.
【0023】また、上記アニオン性界面活性剤として
は、例えば、アシルグルタミン酸塩などのアシルアミノ
酸塩、ラウリン酸ナトリウム及びパルミチン酸ナトリウ
ム等の脂肪酸セッケン、ラウリル硫酸ナトリウム及びラ
ウリル硫酸カリウム等の高級アルキル硫酸エステル塩、
POE−ラウリル硫酸トリエタノールアミン及びPOE
−ラウリル硫酸ナトリウム等のアルキルエーテル硫酸エ
ステル塩、並びにラウロイルサルコシンナトリウム等の
N−アシルサルコシン酸塩等が挙げられる。Examples of the anionic surfactant include acylamino acid salts such as acylglutamates, fatty acid soaps such as sodium laurate and sodium palmitate, and higher alkyl sulfates such as sodium lauryl sulfate and potassium lauryl sulfate. salt,
POE-Triethanolamine lauryl sulfate and POE
-Alkyl ether sulfate ester salts such as sodium lauryl sulfate, N-acyl sarcosinate salts such as sodium lauroyl sarcosine, and the like.
【0024】更に、上記カチオン性界面活性剤として
は、例えば、塩化ステアリルトリメチルアンモニウム及
び塩化ラウリルトリメチルアンモニウム等のアルキルト
リメチルアンモニウム塩、塩化ジステアリルジメチルア
ンモニウムジアルキルジメチルアンモニウム塩、塩化ポ
リ(N,N’−ジメチル−3,5−メチレンピペリジニ
ウム)及び塩化セチルピリジニウム等のアルキルピリジ
ニウム塩、アルキル四級アンモニウム塩、POE−アル
キルアミン、アルキルアミン塩、ポリアミン脂肪酸誘導
体、アミルアルコール脂肪酸誘導体、並びに塩化ベンザ
ルコニウム等が挙げられる。Further, examples of the above-mentioned cationic surfactant include alkyl trimethyl ammonium salts such as stearyl trimethyl ammonium chloride and lauryl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride dialkyl dimethyl ammonium salt, and poly (N, N'-) chloride. Dimethyl-3,5-methylenepiperidinium) and alkylpyridinium salts such as cetylpyridinium chloride, alkyl quaternary ammonium salts, POE-alkylamines, alkylamine salts, polyamine fatty acid derivatives, amyl alcohol fatty acid derivatives, and benzalkonium chloride. Etc.
【0025】更にまた、上記両性界面活性剤としては、
例えば、2−ウンデシル−N,N,N−(ヒドロキシエ
チルカルボキシメチル)−2−イミダゾリンナトリウ
ム、及び2−ココイル−2−イミタゾリニウムヒドロキ
サイド−1−カルボキシエチロキシ−2−ナトリウム塩
等のイミダゾリン系両性界面活性剤、並びに2−ヘプタ
デシル−N−カルボキシメチル−N−ヒドロキシエチル
イミダゾリニウムベタイン、ラウリルジメチルアミノ酢
酸ベタイン、アルキルベタイン、アミドベタイン及びス
ルホベタイン等のベタイン系両性界面活性剤等が挙げら
れる。Furthermore, as the above-mentioned amphoteric surfactant,
For example, 2-undecyl-N, N, N- (hydroxyethylcarboxymethyl) -2-imidazoline sodium, and 2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy-2-sodium salt and the like. Imidazoline-based amphoteric surfactants and betaine-based amphoteric surfactants such as 2-heptadecyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine, lauryldimethylaminoacetic acid betaine, alkyl betaine, amidobetaine and sulfobetaine Can be mentioned.
【0026】また、上記非イオン性界面活性剤として
は、例えば、ソルビタンモノオレエート、ソルビタンモ
ノイソステアレート、ソルビタンモノラウレート、ソル
ビタンモノパルミテート、ソルビタンモノステアレー
ト、ソルビタンセスキオレエート、ソルビタントリオレ
エート、ペンタ−2−エチルヘキシル酸ジグリセロール
ソルビタン及びテトラ−2−エチルヘキシル酸ジグリセ
ロールソルビタン等のソルビタン脂肪酸エステル類、モ
ノステアリン酸グリセリン、α,α’−オレイン酸ピロ
グルタミン酸グリセリン及びモノステアリン酸グリセリ
ンリンゴ酸等のグリセリンポリグリセリン脂肪酸類、モ
ノステアリン酸プロピレングリコール等のプロピレング
リコール脂肪酸エステル類、硬化ヒマシ油誘導体、グリ
セリンアルキルエーテル、POE−ソルビタンモノステ
アレート、POE−ソルビタンモノオエレート及びPO
E−ソルビタンテトラオレエート等のPOE−ソルビタ
ン脂肪酸エステル類、POE−ソルビットモノラウレー
ト、POE−ソルビットモノオレエート、POE−ソル
ビットペンタオレエート及びPOE−ソルビットモノス
テアレート等のPOE−ソルビット脂肪酸エステル類、
POE−グリセリンモノステアレート、POE−グリセ
リンモノイソステアレート及びPOE−グリセリントリ
イソステアレート等のPOE−グリセリン脂肪酸エステ
ル類、POE−モノオレエート、POE−ジステアレー
ト、POE−モノジオレエート及びシステアリン酸エチ
レングリコール等のPOE−脂肪酸エステル類、並びに
POE−ヒマシ油、POE−硬化ヒマシ油、POE−硬
化ヒマシ油モノイソステアレート、POE−硬化ヒマシ
油トリイソステアレート、POE−硬化ヒマシ油モノピ
ログルタミン酸モノイソステアリン酸ジエステル及びP
OE−硬化ヒマシ油マレイン酸等のPOE−ヒマシ油硬
化ヒマシ油誘導体が挙げられる。Examples of the nonionic surfactant include sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate and sorbitan trioleate. Ate, sorbitan fatty acid esters such as diglycerol sorbitan penta-2-ethylhexylate and diglycerol sorbitan tetra-2-ethylhexylate, glyceryl monostearate, α, α′-glyceryl pyroglutamate oleate and glyceryl monostearate malate Polyglycerin fatty acid such as glycerin, propylene glycol fatty acid ester such as propylene glycol monostearate, hydrogenated castor oil derivative, glycerin alkyl ether POE- sorbitan monostearate, POE- sorbitan mono Oe rate and PO
POE-sorbitan fatty acid esters such as E-sorbitan tetraoleate, POE-sorbit monolaurate, POE-sorbit monooleate, POE-sorbit pentaoleate, and POE-sorbit fatty acid esters such as POE-sorbit monostearate ,
POE-glycerin monostearate, POE-glycerin monoisostearate and POE-glycerin triisostearate, and other POE-glycerin fatty acid esters, POE-monooleate, POE-distearate, POE-monodioleate, ethylene glycol distearate and the like. POE-fatty acid esters, as well as POE-castor oil, POE-hardened castor oil, POE-hardened castor oil monoisostearate, POE-hardened castor oil triisostearate, POE-hardened castor oil monopyroglutamic acid monoisostearate diester And P
OE- hydrogenated castor oil POE- castor oil hydrogenated castor oil derivatives such as maleic acid.
【0027】更に、上記水溶性高分子としては、例え
ば、アラビアガム、ペクチン、カンテン、デンプン(コ
メ、トウモロコシ、コムギ)、デキストラン、サクシノ
グルカン、プルラン、カゼイン、アルブミン、ゼラチ
ン、メチルセルロース、ニトロセルロース、ヒドロキシ
プロピルセルロース及びカルボキシメチルセルロースナ
トリウム(CMC)等のセルロース系高分子、アルギン
酸ナトリウム及びアルギン酸プロピレングリコールエス
テル等のアルギン酸系高分子、ポリビニルアルコール、
ポリビニルピロリドン及びカルボキシビニルポリマー
(カーボポール)等のビニル系高分子、ポリエチレング
リコール20000、400000及び600000等
のポリオキシエチレン系高分子、ポリオキシエチレンポ
リオキシプロピレン共重合体共重合系高分子、ポリアク
リル酸ナトリウム等のアクリル系高分子、並びにカチオ
ンポリマー等が挙げられる。更にまた、上記pH調整剤
としては、例えば、乳酸−乳酸ナトリウム、クエン酸−
クエン酸ナトリウム及びリン−リン酸2水素ナトリウム
等の緩衝剤等が挙げられる。Examples of the water-soluble polymer include gum arabic, pectin, agar, starch (rice, corn, wheat), dextran, succinoglucan, pullulan, casein, albumin, gelatin, methylcellulose, nitrocellulose, Cellulosic polymers such as hydroxypropyl cellulose and sodium carboxymethyl cellulose (CMC), alginic acid polymers such as sodium alginate and propylene glycol alginate, polyvinyl alcohol,
Vinyl-based polymers such as polyvinylpyrrolidone and carboxyvinyl polymer (Carbopol), polyoxyethylene-based polymers such as polyethylene glycol 20000, 400,000 and 600,000, polyoxyethylene-polyoxypropylene copolymer copolymer-based polymers, polyacryl Examples thereof include acrylic polymers such as sodium acid salt, and cationic polymers. Furthermore, examples of the pH adjuster include lactic acid-sodium lactate, citric acid-
Examples include buffering agents such as sodium citrate and sodium dihydrogen phosphate-phosphate.
【0028】本発明の皮膚外用剤は、目元に適用するの
に好適であるが、この場合、「目元」とは、個人差もあ
り一義的には規定できないが、代表的には、目頭から水
平方向に15mm以下の点(A点)、このA点から鉛直
下向き方向に20mm以下の点(B点)、目尻から水平
方向に20mm以下の点(C点)、このC点から鉛直下
向き方向に30mm以下の離れた点(D点)のA〜Dの
4点で規定される顔面領域をいうものとする。但し、本
発明の皮膚外用剤を目元以外の領域に適用できないとい
うことではなく、適用した領域中に目元が含まれている
方がよいという趣旨である。The external preparation for skin of the present invention is suitable for application to the eye area. In this case, the "eye area" cannot be unequivocally defined due to individual differences, but typically, A point 15 mm or less in the horizontal direction (point A), a point 20 mm or less in the vertical downward direction from this point A (point B), a point 20 mm or less in the horizontal direction from the outer corner of the eye (point C), a downward direction vertically from this point C In addition, the face area is defined by four points A to D, which are points (D points) apart from each other by 30 mm or less. However, it does not mean that the external preparation for skin of the present invention cannot be applied to a region other than the eye area, and it is preferable that the eye area is included in the applied area.
【0029】[0029]
【実施例】以下、本発明を若干の実施例及び比較例によ
り更に詳細に説明するが、本発明はこれら実施例に限定
されるものではない。EXAMPLES The present invention will be described in more detail with reference to some Examples and Comparative Examples, but the present invention is not limited to these Examples.
【0030】(実施例1〜6、比較例1)下記及び表1
に示す配合組成により、常法に従って各例のクリームを
調製した。得られたクリームにつき、下記の諸試験を実
施した。得られた結果を表2(クマ改善効果)、表3
(小じわ改善効果)及び表4(肌理改善)に示す。(Examples 1 to 6 and Comparative Example 1) The following and Table 1
The creams of the respective examples were prepared according to a conventional method according to the composition shown in (1). The following tests were performed on the obtained cream. The obtained results are shown in Table 2 (bear improving effect) and Table 3.
(The effect of improving fine wrinkles) and Table 4 (improvement of texture) are shown.
【0031】
[クリームの配合]
(水相成分)
グリセリン 5.0%
1,3−ブチレングリコール 6.0%
キサンタンガム 0.3%
ヨクイニン抽出物 0.1%
細胞増殖促進剤(表1記載)
血行促進剤(表1記載)
精製水 残余
(油相成分)
スクワラン 20.0%
自己乳化型モノステアリン酸グリセリン 4.0%
POE(40)ステアリン酸 2.0%
ベヘニルアルコール 2.0%
精製水を加えて全量を100gとし、常法に従ってクリ
ームを調製した。[Composition of Cream] (Aqueous Phase Component) Glycerin 5.0% 1,3-butylene glycol 6.0% Xanthan gum 0.3% Yokuinin extract 0.1% Cell growth promoter (described in Table 1) Blood circulation Accelerator (described in Table 1) Purified water Residue (oil phase component) Squalane 20.0% Self-emulsifying glycerin monostearate 4.0% POE (40) Stearic acid 2.0% Behenyl alcohol 2.0% Purified water was added. The total amount was 100 g, and a cream was prepared according to a conventional method.
【0032】[0032]
【表1】 [Table 1]
【0033】(1)クマ改善効果
(試験方法)目の下のクマが目立つ20代女性10名の
右目元に4週間連続塗布し、その効果を評価した。即
ち、被験者の右目元に1日1回、所定の配合組成を有す
る各例のクリームをそれぞれ約0.5g塗布し、試験開
始前及び試験終了後の目の下のクマの状態を以下の判定
基準により判定した。なお、左目元は試料を塗布せず対
照とした。得られた結果を表2に示す。
(判定基準)
著 効;明瞭で細かい肌理が観察される
有 効;明瞭だがやや粗い肌理が観察される
やや有効;やや不明瞭な肌理が観察される
無 効;不明瞭な肌理が観察される
(判定)
◎;被験者のうち著効及び有効を示す割合が8名以上の
場合
○;被験者のうち著効及び有効を示す割合が5名〜7名
の場合
△;被験者のうち著効及び有効を示す割合が2名〜4名
の場合
×;被験者のうち著効及び有効を示す割合が2名未満の
場合(1) Bear Improvement Effect (Test Method) The effect was evaluated by continuously applying it to the right eye area of 10 women in their twenties who had outstanding bears under the eyes for 4 weeks. That is, about 0.5 g of the cream of each example having a predetermined composition was applied once a day to the right eye of the subject, and the state of the bear under the eyes before the start of the test and after the end of the test was evaluated according to the following criteria. It was judged. The left eye area was not coated with the sample and was used as a control. The obtained results are shown in Table 2. (Judgment Criteria) Efficacy; Clear and fine texture is observed Effective; Clear but slightly rough texture is observed Slightly effective; Slightly unclear texture is observed Ineffective; Unclear texture is observed (Judgment) ⊙: The proportion of the subjects showing excellent response and efficacy is 8 or more ○: The proportion of the subjects showing excellent response and efficacy is 5 to 7 Δ: Remarkable and effective among the subjects When the ratio showing 2 is from 4 to 4 people; when the ratio showing excellent response and efficacy among the subjects is less than 2 people
【0034】(2)目尻の小じわ改善効果
(試験方法)目尻に深さ50〜100μm程度の小じわ
を有する20代女性10名に4週間連続塗布し、その効
果を評価した。即ち、被験者の右目尻試験部位に1日1
回、各例のクリームをそれぞれ約0.5g塗布し、試験
開始前及び試験終了後の目尻に対して、山田粧業製二剤
混合型レプリカ剤スキンキャストを用いてレプリカを採
取し、下記の判定基準により判定した。左目尻は試料を
塗布せずに対照とした。得られた結果を表3に示す。
(判定基準)
著 効;顕著な改善
有 効;中程度の改善
やや有効;軽度の改善
無 効;変化なし
(判定)
◎;被験者のうち著効及び有効を示す割合が8名以上の
場合
○;被験者のうち著効及び有効を示す割合が5名〜7名
の場合
△;被験者のうち著効及び有効を示す割合が2名〜4名
の場合
×;被験者のうち著効及び有効を示す割合が2名未満の
場合(2) Effect of improving fine wrinkles on the outer corners of the eyes (test method) The effect was evaluated by continuously applying it to 10 women in their 20s having fine wrinkles on the outer corners of the eyes at a depth of about 50 to 100 μm for 4 weeks. That is, 1 day a day on the test site of the right outer corner of the subject
Each time, about 0.5 g of the cream of each example was applied, and a replica was collected using a two-agent mixed type replica agent skin cast manufactured by Yamada Cosmetics Co., Ltd. on the outer corners of the eye before and after the test. It was judged according to the standard. The left outer corner of the eye was used as a control without applying the sample. The results obtained are shown in Table 3. (Judgment Criteria) Effective: Significant improvement Effective; Moderate improvement Slightly effective; Mild improvement not effective; No change (judgment) ◎: When the proportion of subjects showing excellent or effective is 8 or more ○ ; When the rate of marked response and efficacy among the subjects is 5 to 7 △: When the rate of marked response and efficacy among the subjects is 2 to 4 ×: Indicates the efficacy and efficacy among the subjects If the ratio is less than 2 people
【0035】(3)むくみ改善効果
(試験方法)目の下のむくみが目立つ20代女性10名
の右目元に4週間連続塗布し、その効果を評価した。即
ち、被験者の頬部位に1日1回、被験者の右目の下に1
日1回、各例のクリームをそれぞれ約0.5g塗布し、
試験開始前及び試験終了後の目の下のむくみの状態を下
記の判定基準により判定した。なお、左目元は試料を塗
布せず対照とした。得られた結果を表4に示す。
(判定基準)
著 効;顕著な改善
有 効;中程度の改善
やや有効;軽度の改善
無 効;変化なし
(判定)
◎;被験者のうち著効及び有効を示す割合が8名以上の
場合
○;被験者のうち著効及び有効を示す割合が5名〜7名
の場合
△;被験者のうち著効及び有効を示す割合が2名〜4名
の場合
×;被験者のうち著効及び有効を示す割合が2名未満の
場合(3) Swelling Improvement Effect (Test Method) 10 women in their twenties who had a noticeable swelling under the eyes were continuously applied to the right eye area for 4 weeks, and the effect was evaluated. That is, once a day on the subject's cheek region, and below the subject's right eye, 1
Once a day, apply about 0.5 g of each example cream,
The state of swelling under the eyes before the start of the test and after the end of the test was judged according to the following judgment criteria. The left eye area was not coated with the sample and was used as a control. The results obtained are shown in Table 4. (Judgment Criteria) Effective: Significant improvement Effective; Moderate improvement Slightly effective; Mild improvement not effective; No change (judgment) ◎: When the proportion of subjects showing excellent or effective is 8 or more ○ ; When the rate of marked response and efficacy among the subjects is 5 to 7 △: When the rate of marked response and efficacy among the subjects is 2 to 4 ×: Indicates the efficacy and efficacy among the subjects If the ratio is less than 2 people
【0036】[0036]
【表2】 [Table 2]
【0037】表2から明らかなように、本発明の範囲に
属する実施例1〜6のクリームにはクマ改善効果があ
り、特にアロエ又はアーモンドからの抽出物を配合する
と、この改善効果が高くなることが分かる。As is clear from Table 2, the creams of Examples 1 to 6 which belong to the scope of the present invention have a bear improving effect, and particularly when an extract from aloe or almond is added, this improving effect is enhanced. I understand.
【0038】[0038]
【表3】 [Table 3]
【0039】表3から明らかなように、本発明の範囲に
属する実施例1〜6のクリームには小ジワ改善効果があ
り、特にアロエ又はアーモンドからの抽出物を配合する
と、この改善効果が高くなることが分かる。As is clear from Table 3, the creams of Examples 1 to 6 which belong to the scope of the present invention have an effect of improving fine wrinkles, and particularly when an extract from aloe or almond is added, this effect of improvement is high. I see.
【0040】[0040]
【表4】 [Table 4]
【0041】表4から明らかなように、本発明の皮膚外
用剤の一例である実施例1〜6のクリームにはむくみ改
善効果があり、特にアロエ又はアーモンドからの抽出物
を配合すると、その改善効果が高くなることが分かる。As is clear from Table 4, the creams of Examples 1 to 6, which are one example of the external preparation for skin of the present invention, have an effect of improving swelling, and in particular, when the extract from aloe or almond is added, the improvement is achieved. You can see that the effect is high.
【0042】[0042]
【発明の効果】以上説明してきたように、本発明によれ
ば、ヨクイニンなどに所定成分を配合することとしたた
め、ヨクイニンを含有する新規用途に係る組成物であっ
て、クマ、小じわ及びむくみを改善し得る目元向き又は
目元用の皮膚外用剤を提供することができる。Industrial Applicability As described above, according to the present invention, since the predetermined components are added to Yokuinin or the like, the composition for Yokuinin is a novel use composition, and bears, fine wrinkles and swelling are eliminated. It is possible to provide a skin external preparation for or around the eyes that can be improved.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 35/78 A61K 35/78 H J N Q S T U V A61P 3/02 109 A61P 3/02 109 9/00 9/00 17/16 17/16 43/00 107 43/00 107 Fターム(参考) 4C083 AA111 AA112 AC012 AC072 AC111 AC122 AC182 AD352 AD661 CC05 DD31 EE06 EE07 EE12 EE13 4C086 AA01 AA02 BA09 MA03 MA04 MA05 MA28 MA63 NA14 ZA36 ZA89 ZB22 ZC29 4C088 AB12 AB19 AB26 AB34 AB38 AB40 AB52 AB59 AB86 BA07 BA08 CA03 MA08 MA28 MA63 ZA36 ZA89 ZB22 ZC29 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 35/78 A61K 35/78 H J N Q S T U V A61P 3/02 109 A61P 3/02 109 9 / 00 9/00 17/16 17/16 43/00 107 43/00 107 F term (reference) 4C083 AA111 AA112 AC012 AC072 AC111 AC122 AC182 AD352 AD661 CC05 DD31 EE06 EE07 EE12 EE13 4C086 AA01 AA02 BA09 MA03 MA04 MA05 MA28 MA63 NA14 ZA36 ZA89 ZB22 ZC29 4C088 AB12 AB19 AB26 AB34 AB38 AB40 AB52 AB59 AB86 BA07 BA08 CA03 MA08 MA28 MA63 ZA36 ZA89 ZB22 ZC29
Claims (6)
胞増殖促進剤と、血行促進剤とを配合して成ることを特
徴とする目元向き皮膚外用剤。1. A skin external preparation for the eyes, comprising a mixture of yochinin and / or an extract thereof, a cell growth promoter and a blood circulation promoter.
ウタンポポ、センキュウ、ソウハクヒ、ニンジン及びホ
ップから成る群より選ばれた少なくとも1種の植物、及
び/又はこれらの植物若しくは植物の組合せからの抽出
物であることを特徴とする請求項1に記載の皮膚外用
剤。2. The cell growth promoting agent is an extract from at least one plant selected from the group consisting of aloe, dandelion, senkyu, sokuhaku, carrot and hop, and / or a plant or a combination of these plants. The external preparation for skin according to claim 1, which is:
はその誘導体であることを特徴とする請求項1又は2に
記載の皮膚外用剤。3. The external skin preparation according to claim 1, wherein the blood circulation promoting agent is vitamin E and / or a derivative thereof.
生、シソ及びカボチャから成る群より選ばれた少なくと
も1種の植物、及び/又はこれらの植物若しくは植物の
組合せからの抽出物であることを特徴とする請求項1又
は2に記載の皮膚外用剤。4. The blood circulation promoter is an extract from at least one plant selected from the group consisting of almond, peanut, perilla and pumpkin, and / or a plant or a combination of these plants. The external preparation for skin according to claim 1 or 2.
とを特徴とする請求項1〜4のいずれか1つの項に記載
の皮膚外用剤。5. The external preparation for skin according to any one of claims 1 to 4, which further comprises pentanediol.
〜6のいずれか1つの項に記載の皮膚外用剤。6. The method according to claim 1, which is used for an eye area.
The external preparation for skin according to any one of 1 to 6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002036377A JP2003238383A (en) | 2002-02-14 | 2002-02-14 | Skin care preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002036377A JP2003238383A (en) | 2002-02-14 | 2002-02-14 | Skin care preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2003238383A true JP2003238383A (en) | 2003-08-27 |
Family
ID=27778279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002036377A Pending JP2003238383A (en) | 2002-02-14 | 2002-02-14 | Skin care preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2003238383A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005170830A (en) * | 2003-12-10 | 2005-06-30 | Asahi Soft Drinks Co Ltd | Melanin production inhibiting composition |
JP2005343864A (en) * | 2004-06-07 | 2005-12-15 | Kuraray Co Ltd | Topical skin preparation |
JP2007254345A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Maillard reaction inhibitor, skin care preparation containing the same and food and beverage |
JP2018505883A (en) * | 2015-02-04 | 2018-03-01 | エルヴェエムアッシュ ルシェルシュ | Use of peppermint extract in cosmetics |
-
2002
- 2002-02-14 JP JP2002036377A patent/JP2003238383A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005170830A (en) * | 2003-12-10 | 2005-06-30 | Asahi Soft Drinks Co Ltd | Melanin production inhibiting composition |
JP2005343864A (en) * | 2004-06-07 | 2005-12-15 | Kuraray Co Ltd | Topical skin preparation |
JP2007254345A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Maillard reaction inhibitor, skin care preparation containing the same and food and beverage |
JP2018505883A (en) * | 2015-02-04 | 2018-03-01 | エルヴェエムアッシュ ルシェルシュ | Use of peppermint extract in cosmetics |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3609834B2 (en) | Skin preparation | |
KR20100088580A (en) | Personal care sunscreen compositions having reduced eye irritation | |
EP2213336A2 (en) | Personal care sunscreen compositions having reduced eye irritation | |
WO2012017734A1 (en) | Skin cosmetic | |
JP2003026546A (en) | Hair tonic composition | |
US20110086075A1 (en) | Personal care sunscreen compositions having reduced eye irritation | |
JP2001233754A (en) | Emulsion type skin care preparation | |
JP2006045186A (en) | Lamella structure regenerating agent and skin care preparation for external use | |
JP2003034631A (en) | Fibroblast proliferation-promoting agent and aging- preventing cosmetics | |
JP6654369B2 (en) | Elastase inhibitor | |
JPH11139951A (en) | Cosmetic | |
JP2003238384A (en) | Skin care preparation | |
JP4887050B2 (en) | Inadequate keratinization inhibitor, pore reducing agent | |
JP2003238383A (en) | Skin care preparation | |
TW200916118A (en) | External preparation for skin | |
JP2005132828A (en) | Composition for external application | |
JP2004010480A (en) | Peeling agent for horny layer | |
JP2003238341A (en) | Skin care preparation | |
JP4575868B2 (en) | Wrinkle improving agent, keratinization inhibitor, rough skin prevention / improving agent and pore reducing agent | |
JP5000049B2 (en) | Anti-aging agent | |
JP2013203678A (en) | Oil-in-water type emulsified skin cosmetic | |
JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
JP2002128654A (en) | Skin care preparation | |
JP2005281197A (en) | Parakeratosis inhibitor, pore reducing agent, and skin external preparation | |
JP2003238385A (en) | Sustainable moisturizing preparation and skin care preparation containing the same |